A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Clinical trial NCT02727699 · COMPLETED
Trial details
- NCT number
- NCT02727699
- Sponsor
- Actinogen Medical
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-23
- Primary completion
- 2019-03-15
- Enrollment
- 185
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.